Study Overview
This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.
Description
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT05620836\]).
Official Title
A Phase 3, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Quick Facts
Study Start:2024-01-30
Study Completion:2026-12-26
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
| Inclusion Criteria | Exclusion Criteria |
|---|
| |
Contacts and Locations
Study Locations (Sites)
Investigative Site US303
Phoenix, Arizona, 85006
United States
Investigator Site US240
Scottsdale, Arizona, 85255
United States
Investigative Site US307
Fort Smith, Arkansas, 72916
United States
Investigative Site US214
Rogers, Arkansas, 72758
United States
Investigative Site US315
Laguna Niguel, California, 92677
United States
Investigator Site US223
Los Angeles, California, 90033
United States
Investigative Site US222
Oakland, California, 94611
United States
Investigative Site US226
San Diego, California, 92103
United States
Investigative Site US233
Washington, District of Columbia, 20060
United States
Investigative Site US228
Brandon, Florida, 33511
United States
Investigative Site US309
Clearwater, Florida, 33614
United States
Investigative Site US317
Hialeah, Florida, 33012-3618
United States
Investigative Site US306
Hollywood, Florida, 33021
United States
Investigative Site US320
Hollywood, Florida, 33021
United States
Investigative Site US316
Maitland, Florida, 32751
United States
Investigative Site US227
Margate, Florida, 33063
United States
Investigative Site US204
Miami, Florida, 33136
United States
Investigative Site US321
North Miami Beach, Florida, 33162-4708
United States
Investigative Site US200
Ocala, Florida, 34470
United States
Investigative Site US201
Tampa, Florida, 33613
United States
Investigative Site US311
Marietta, Georgia, 30060
United States
Investigative Site US319
Skokie, Illinois, 60077
United States
Investigative Site US220
West Dundee, Illinois, 60118
United States
Investigative Site US206
Indianapolis, Indiana, 46250
United States
Investigator Site US341
Bowling Green, Kentucky, 42104
United States
Investigative Site US209
Louisville, Kentucky, 40241
United States
Investigative Site US305
Baton Rouge, Louisiana, 70809
United States
Investigative Site US207
Metairie, Louisiana, 70006
United States
Investigative Site US229
New Orleans, Louisiana, 70115
United States
Investigative Site US224
Baltimore, Maryland, 21287
United States
Investigator Site US325
Marriottsville, Maryland, 21104
United States
Investigative Site US225
Boston, Massachusetts, 02115
United States
Investigative Site US304
Boston, Massachusetts, 02215
United States
Investigative Site US310
Needham, Massachusetts, 02492
United States
Investigative Site US221
Quincy, Massachusetts, 02169
United States
Investigative Site US213
Fort Gratiot, Michigan, 48059
United States
Investigative Site US217
Waterford, Michigan, 48328
United States
Investigative Site US212
Minneapolis, Minnesota, 55455
United States
Investigative Site US302
Saint Louis, Missouri, 63110
United States
Investigator Site US239
Omaha, Nebraska, 68144
United States
Investigative Site US318
Portsmouth, New Hampshire, 03801
United States
Investigative Site US230
East Windsor, New Jersey, 08520
United States
Investigative Site US324
Forest Hills, New York, 11375
United States
Investigative Site US202
New York, New York, 10028
United States
Investigative Site US210
Rochester, New York, 14642
United States
Investigative Site US205
Chapel Hill, North Carolina, 27516
United States
Investigative Site US215
Bexley, Ohio, 43209
United States
Investigator Site US330
Boardman, Ohio, 44512
United States
Investigative Site US314
Cincinnati, Ohio, 45219
United States
Investigator Site US312
Cleveland, Ohio, 44106
United States
Investigative Site US203
Gahanna, Ohio, 43230
United States
Investigative Site US301
Portland, Oregon, 97201
United States
Investigative Site US232
Murfreesboro, Tennessee, 37130
United States
Investigator Site US235
Arlington, Texas, 76011
United States
Investigative Site US218
Bellaire, Texas, 77401
United States
Investigator Site US238
Pflugerville, Texas, 78660
United States
Investigative Site US300
Plano, Texas, 75025
United States
Investigative Site US313
Norfolk, Virginia, 23502
United States
Investigative Site US308
Spokane, Washington, 99202
United States
Collaborators and Investigators
Sponsor: Incyte Corporation
- Incyte Medical Monitor, STUDY_DIRECTOR, Incyte Corporation
Study Record Dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
Study Start Date2024-01-30
Study Completion Date2026-12-26
Study Record Updates
Study Start Date2024-01-30
Study Completion Date2026-12-26
Terms related to this study
Keywords Provided by Researchers
- Hidradenitis Suppurativa
- Hidradenitis
- Acne inversa
- HS
- Povorcitinib
- Long-Term Extension (LTE)
- INCB054707
Additional Relevant MeSH Terms
- Hidradenitis Suppurativa (HS)